Not For Human Consumption
Grey market peptides have built a parallel pharmaceutical infrastructure under the thinnest regulatory pretense. The data reveals a cultural contradiction that extends far beyond weight loss.
The FDA classifies BPC-157 as Category 2 (ineligible for compounding) while Telegram communities with 35,000 members crowdsource third-party lab testing at $850 per batch. Eli Lilly’s retatrutide achieves 28.7% weight loss in Phase 3 trials while Chinese suppliers ship enough semaglutide API to produce over one billion starter doses. At a December 2025 …
